PRA completes merger of RPS

- Last updated on GMT

Related tags: Completeness, Contract research organization

PRA completes merger of RPS
The merger of PRA and RPS has been completed, creating the fourth largest contract research organisation (CRO).

The merger was officially signed off yesterday, with ReSearch Pharmaceutical Services (RPS) now operating as PRA’s Strategic Solutions Division, under direction from PRA International’s CEO, Colin Shannon.

“This begins a new chapter for both organisations,”​ said Shannon. “As a division of PRA, the RPS Strategic Solutions Division will continue to operate as RPS has previously, which should enable a seamless integration with absolutely no disruption for our clients.”

Harris Koffer and Samir Shah, former RPS CEO and President, respectively, will serve as President and COO of the Strategic Solutions Division.

“We are excited about joining the PRA family and leveraging the enhanced capabilities of the combined company to deliver greater value and innovation for our clients and employees,”​ said Koffer.

The announcement of the merger came in July​, and was greeted by analysts as a mostly positive move for the two mid-sized CROs.

“There are too many mid-sized vendors in the industry and this is another small step in the overall industry consolidation that will occur over the next few years,”​ said David Blume from Edgemont Capital Partners, at the time.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more